Answers are grounded in this paper and cite their sources.
Estimates show low rates of cessation pharmacotherapy among tobacco users in Medicaid, indicating a need for improvement.
Tobacco use drives large health and fiscal costs for Medicaid, yet few enrollees who use these products receive cessation pharmacotherapy. We estimated that 10.4 percent of daily tobacco or nicotine users received cessation medications in 2024, and Medicaid programs spent $137.6 million on such treatments that year. State-level treatment rates ranged from 1.3 percent to 26.6 percent.
No takes yet. Share an insight, caveat, or question.
Clemans-Cope et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: